Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Completed · Phase 1

Conditions studied: Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of hu14.18-interleukin-2 fusion protein in treating children who have refractory or recurrent neuroblastoma or other tumors.

Key facts

Study ID
NCT00003750
Run by
Children's Oncology Group
People needed
28
Starts
2001-10-01
Expected to finish
2005-09-01
Last updated by the study team
2014-08-08

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.